Vistagen Therapeutics (VTGN) Total Liabilities (2011 - 2026)
Vistagen Therapeutics (VTGN) posted Total Liabilities of $13.0 million for Q1 2026, down 7.72% sequentially from $14.1 million in Q4 2025, and down 6.5% YoY from $14.0 million in Q1 2025.
Vistagen Therapeutics (VTGN) Total Liabilities (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Total Liabilities for 14 years, with the latest figure at $13.0 million in Q1 2026.
- Quarterly Total Liabilities fell 6.5% year-over-year to $13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.0 million (down 6.5% YoY) and the FY2026 annual result came in at $13.0 million, down 6.5% from the prior year.
- Total Liabilities eased to $13.0 million in Q1 2026 per VTGN's latest filing, from $14.1 million in the prior quarter.
- Over five years, Total Liabilities peaked at $14.6 million in Q3 2025 and troughed at $6.6 million in Q3 2023.
- A 5-year average of $10.6 million and a median of $9.9 million in 2022 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities plunged 44.07% in 2022, then surged 53.22% in 2025.
- Over 5 years, Total Liabilities stood at $9.0 million in 2022, then slipped by 13.85% to $7.8 million in 2023, then jumped by 43.71% to $11.2 million in 2024, then advanced by 26.38% to $14.1 million in 2025, then decreased by 7.72% to $13.0 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $13.0 million, $14.1 million, and $14.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.61 Bn | 131.75 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.28 Bn | 60.09 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 59.14 Bn | 54.00 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.83 Bn | 28.52 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 10.03 Bn |
| 10 | Vistagen Therapeutics | 10.54 Mn | 10.54 Mn | - | 11.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.04 Mn |
| Dec 31, 2025 | 14.14 Mn |
| Sep 30, 2025 | 14.59 Mn |
| Jun 30, 2025 | 12.16 Mn |
| Mar 31, 2025 | 13.95 Mn |
| Dec 31, 2024 | 11.19 Mn |
| Sep 30, 2024 | 9.52 Mn |
| Jun 30, 2024 | 8.75 Mn |
| Mar 31, 2024 | 9.37 Mn |
| Dec 31, 2023 | 7.78 Mn |
| Sep 30, 2023 | 6.55 Mn |
| Jun 30, 2023 | 8.18 Mn |
| Mar 31, 2023 | 9.01 Mn |
| Dec 31, 2022 | 9.03 Mn |
| Sep 30, 2022 | 11.10 Mn |
| Jun 30, 2022 | 12.67 Mn |
| Mar 31, 2022 | 9.93 Mn |
| Dec 31, 2021 | 10.56 Mn |
| Sep 30, 2021 | 19.84 Mn |
| Jun 30, 2021 | 18.29 Mn |